NASDAQ$IMUX
Immunic Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Announced first quarter 2023 financial results and provided a corporate update, highlighting positive results from the Phase 1b clinical trial of IMU-856 in celiac disease and progress in the Phase 2 CALLIPER trial of Vidofludimus Calcium in progressive multiple sclerosis.
Immunic reported positive results from the Phase 1b clinical trial of IMU-856 in celiac disease, demonstrating improvements in histology, disease symptoms, biomarkers, and nutrient absorption. The company is preparing for a Phase 2b clinical trial of IMU-856 in celiac disease patients. Additionally, data from the maintenance phase of the Phase 2b CALDOSE-1 trial of vidofludimus calcium in ulcerative colitis showed statistically significant activity compared to placebo. The company expects an interim biomarker analysis from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive MS in the second half of 2023.
- Reported positive data from the maintenance phase of the phase 2b CALDOSE-1 trial of vidofludimus calcium in patients with moderate-to-severe ulcerative colitis (UC).
- Announced positive results from our phase 1b clinical trial of IMU-856 in patients with celiac disease.
- Preparing for a phase 2b clinical trial of IMU-856 in ongoing active celiac disease patients.
- Next value inflection point will be a second half 2023 interim biomarker analysis of our phase 2 CALLIPER trial in progressive MS.
Headline financials
Revenue & EPS history
Immunic · Revenue · Quarterly
$0
Forward guidance
Immunic expects its cash, cash equivalents and investments to fund operations into the fourth quarter of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
+0.1%
Avg return
Earnings day
-0.1%
Avg return
5 days after
-4.5%
Avg return
30 days after
37%
17 / 46 earnings
Positive
+37.0%
Q2 2022
Best reaction
-16.4%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.8% | -1.7% | +15.5% | |
| Q3 2025 | -6.3% | +0.0% | -18.2% | |
| Q4 2024 | -2.1% | -28.1% | -22.7% | |
| Q1 2025 | -4.8% | -7.8% | -26.4% | |
| Q3 2024 | +0.0% | -2.5% | +8.5% | |
| Q1 2024 | -10.1% | -9.1% | -10.9% | |
| Q4 2023 | -4.7% | +8.6% | +3.1% | |
| Q3 2023 | +3.2% | +9.4% | +50.7% | |
| Q2 2023 | -6.9% | -8.8% | -20.4% | |
| Q1 2023 | -2.8% | -5.0% | -3.9% | |
| Q4 2022 | +0.0% | +4.8% | -21.7% | |
| Q3 2022 | -11.1% | -12.3% | -20.5% | |
| Q2 2022 | +37.0% | +29.0% | +16.7% | |
| Q1 2022 | +0.4% | +12.1% | -25.1% | |
| Q4 2021 | -9.4% | -3.2% | -0.4% | |
| Q3 2021 | +2.1% | +1.1% | -16.7% | |
| Q2 2021 | +21.7% | +17.1% | +25.5% | |
| Q1 2021 | -8.3% | -8.1% | -2.8% | |
| Q4 2020 | +0.5% | -1.7% | -5.7% | |
| Q3 2020 | +4.4% | +7.3% | +10.7% | |
| Q2 2020 | +27.9% | +8.7% | -11.6% | |
| Q1 2020 | +18.3% | +20.3% | +53.9% | |
| Q4 2019 | -16.4% | -19.3% | +19.3% | |
| Q3 2019 | -6.4% | -6.2% | -17.3% | |
| Q2 2019 | +0.4% | +4.6% | +6.4% | |
| Q1 2019 | +7.1% | -16.1% | -58.8% | |
| Q4 2018 | -11.1% | -8.3% | -17.8% | |
| Q3 2018 | -7.0% | -9.9% | -18.9% | |
| Q2 2018 | -2.8% | +6.8% | -17.0% | |
| Q1 2018 | +0.9% | +2.7% | -11.7% | |
| Q4 2017 | -6.5% | +2.6% | +0.0% | |
| Q3 2017 | -4.5% | +4.5% | -7.3% | |
| Q2 2017 | +17.3% | +11.5% | +17.3% | |
| Q1 2017 | -4.0% | -17.3% | -17.3% | |
| Q4 2016 | -1.2% | +1.2% | -11.6% | |
| Q3 2016 | -1.0% | +8.6% | -4.8% | |
| Q2 2016 | +1.3% | -0.5% | -5.8% | |
| Q1 2016 | +3.9% | — | — | |
| Q4 2015 | -4.9% | — | — | |
| Q3 2015 | -3.9% | — | — | |
| Q2 2015 | +15.8% | — | — | |
| Q1 2015 | -5.6% | — | — | |
| Q4 2014 | -9.0% | — | — | |
| Q3 2014 | +5.0% | — | — | |
| Q2 2014 | -7.2% | — | — | |
| Q1 2014 | -0.1% | — | — | |
| Q2 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro